AQEMIA AI-Driven Drug Discovery Platform
Generative AI and deep physics platform for next-generation drug discovery
Platform · OtherCompany source
Company profile
About Aqemia
Aqemia is a biotechnology company reinventing drug discovery through the integration of generative AI and deep physics. The company operates at the intersection of technology and life sciences, developing a proprietary drug discovery pipeline that goes beyond conventional and AI-augmented approaches. Aqemia's platform leverages advanced computational chemistry, machine learning, and quantum physics to design and optimize novel drug candidates at scale. With a multidisciplinary team spanning AI, software engineering, computational chemistry, and drug discovery, Aqemia is building a portfolio of innovative therapeutics. The company maintains offices in both Paris, France and London, UK, positioning itself as a European leader in AI-driven drug discovery. Aqemia's mission-driven culture emphasizes collaboration, ownership, and meaningful impact in advancing medicines that address unmet medical needs.
Company description Aqemia official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Aqemia?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsEurope · France · United Kingdom
Company sourceOfficial website
Company milestones
Platform expansion
Participating in J.P. Morgan Healthcare Conference 2026 (January), Jefferies Global Healthcare Conference 2025 (November), and Jefferies European Disruptive Tech Conference (October 2025)
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Scaffold-Constrained Molecular Generation.Journal of chemical information and modeling · Dec 28, 2020
Tackling Solvent Effects by Coupling Electronic and Molecular Density Functional Theory.Journal of chemical theory and computation · Nov 10, 2020
Predicting Hydration Free Energies of the FreeSolv Database of Drug-like Molecules with Molecular Density Functional Theory.Journal of chemical information and modeling · Jul 27, 2020
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Aqemia
Recent articles published on Aqemia's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.